Potential of endogenous regenerative technology for in situ regenerative medicine
Endogenous regenerative technology involves the use of a patient's biologically active proteins, growth factors and biomaterial scaffolds.
Potential of endogenous regenerative technology for in situ regenerative medicine
A new hope for a therapy against retinitis pigmentosa
Antabuse may help revive vision in people with progressive blinding disorders
New Treatments for Retinitis Pigmentosa
FDA grants orphan drug designation for RP treatment
FDA grants fourth ODD for treatment of PDE6B gene mutation-associated retinal diseases
Understanding the molecular mechanisms underlying retina degeneration in INPP5E-Joubert Syndrome
First Gene Therapy FDA-Approved for an Inherited Retinal Disease
FDA Approves Gene Therapy for Inherited Blindness Developed by the UPenn and CHOP